Thalidomide and its analogues in the treatment of Multiple Myeloma

被引：0
作者：
Tahir Latif
Nabeel Chauhan
Rashid Khan
Andrea Moran
Saad Z Usmani
机构：
[1] University of Cincinnati School of Medicine,UC Cancer Institute, Division of Hematology
[2] University of Arkansas for Medical Sciences,Oncology
[3] University of Connecticut Health Center,Myeloma Institute for Research & Therapy
来源：
Experimental Hematology & Oncology | / 1卷 / 1期
关键词：
Multiple Myeloma; Thalidomide; Lenalidomide; Pomalidomide; Therapy;
D O I：
10.1186/2162-3619-1-27
中图分类号：
学科分类号：
摘要：
Multiple myeloma is an incurable malignant disorder of mature B-cells that predominantly affects the elderly. The immunomodulatory drug (IMiD) thalidomide and its newer analogs demonstrate increased antitumor activity, and have had a positive impact on the natural history of multiple myeloma. Recent advances in the clinical application of these agents and in our understanding of their mechanism of action, and toxicity have made safer and smarter use of these drugs possible. This review discusses the available information regarding mechanisms of action, toxicity and clinical results on thalidomide, lenalidomide and pomalidomide in the therapy of multiple myeloma.
引用
收藏
相关论文
共 172 条
[41]  
Saliba R(2011)High expression of thalidomide binding protein cereblon(CRBN) is associated with improved clinical response in patients with mutiple myeloma treated with lenalidomide and dexamethasone Blood 118 2879-4465
[42]  
Thandi R(2008)Thalidomide for treatment of multiple myeloma: 10 years later Blood 111 3968-1939
[43]  
Attal M(2008)Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomized trial Lancet 370 1209-undefined
[44]  
Lauwers-Cances V(2007)Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 Br J Haematol 138 176-undefined
[45]  
Marit G(2012)The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and meta-analysis Blood 119 7-undefined
[46]  
McCarthy PL(2010)Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Lancet Oncol 11 29-undefined
[47]  
Owzar K(2008)BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma Blood 111 1101-undefined
[48]  
Hofmeister CC(2007)Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA–Italian Multiple Myeloma Network J Clin Oncol 25 4459-undefined
[49]  
Palumbo A(2008)Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: Encouraging efficacy in high risk groups with updated results of a phase I/II study Blood 112 92-undefined
[50]  
Hajek R(2010)Phase II trail of lenalidomide, bortezomib and dexamethasone in patients (pts) with replased and replased/refractory multiple myeloma (MM): Updated efficacy and safety data after >2 years of follow up Blood 116 3049-undefined
12345678910